Ahn MJ, Cho BC, Ou X, Walding A, et al. Brief Report: Osimertinib Plus Durvalumab in Patients with EGFR-Mutated, Advanced Non-Small Cell Lung Cancer: A Phase 1b, Open-Label, Multicenter Trial. J Thorac Oncol 2022 Feb 15. pii: S1556-0864(22)00081.
PMID: 35181499